Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients.

Kazuhiko Toyooka1, Yuichiro Watanabe, Shuji Iritani

  • 1Department of Molecular Neurobiology, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, 951-8585, Niigata, Japan.

Neuroscience Research
|June 14, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Region-specific dysregulation of proline metabolic enzymes underlying mitochondrial dysfunction in the postmortem brains of patients with schizophrenia.

Journal of psychiatric research·2026
Same author

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

Expert review of anticancer therapy·2026
Same author

A protective role for APP in nuclear waste clearance via lysosomal exocytosis.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Mass spectrometry-based proteomic profiling of human tauopathy brains suggests mitochondria-associated alterations.

Frontiers in molecular neuroscience·2026
Same author

Unclassifiable senile plaques and extensive cerebral amyloid angiopathy involving spinal and bridging vessels in autopsied patients with Down syndrome.

Free neuropathology·2026
Same author

The mTOR-Dop1a-Agpat2 axis regulates nuclear phospholipid homeostasis.

iScience·2026

Interleukin-1 receptor antagonist (IL-1RA) levels are reduced in the prefrontal cortex of schizophrenia patients, suggesting a specific brain pathology. This reduction in IL-1RA may indicate an immunopathological trait in schizophrenia.

Area of Science:

  • Neuroscience
  • Immunology
  • Psychiatry

Background:

  • Interleukin-1 (IL-1) signaling influences stress responses and is linked to psychiatric disorders.
  • Understanding IL-1's role in schizophrenia brain pathology is crucial.

Purpose of the Study:

  • To investigate the contribution of IL-1 signaling to schizophrenia's brain pathology.
  • To measure IL-1beta and IL-1 receptor antagonist (IL-1RA) levels in postmortem brain tissues of schizophrenia patients.

Main Methods:

  • Quantified protein and mRNA levels of IL-1beta and IL-1RA in prefrontal cortex, parietal cortex, putamen, and hypothalamus.
  • Assessed IL-1 receptor type 1 protein levels.
  • Compared these levels between schizophrenic patients and controls.

Related Experiment Videos

Main Results:

  • IL-1RA protein and mRNA levels were significantly decreased in the prefrontal cortex of schizophrenia patients.
  • IL-1beta levels and IL-1 receptor type 1 levels were not significantly altered in the examined brain regions.
  • Increased IL-1RA serum levels were observed in schizophrenia patients, particularly in drug-free individuals.

Conclusions:

  • Chronic schizophrenia is associated with down-regulated IL-1RA production in the prefrontal cortex.
  • Reduced IL-1RA in the prefrontal cortex may represent an immunopathological characteristic of schizophrenia.
  • Peripheral IL-1RA levels do not directly reflect central changes in the prefrontal cortex.